Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Influenza Vaccine with Additional H3 Antigen in Healthy Adults
NCT06507553Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Augment-Tasmania influenza vaccine, TIV-2X Darwin influenza vaccine and Trivalent-Tasmania influenza vaccine in influenza (8 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse event at 30 minutes, Number of participants with solicited injection site reactions at 7 days and 3 more. Started Aug 2024; status: completed.
02
Drugs
Augment-Tasmania influenza vaccineTIV-2X Darwin influenza vaccineTrivalent-Tasmania influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06507553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507553.